Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
Reset 

HomeVi announces the launch of syndication of EUR 1,020 million Senior Secured Term Loan B for debt refinancing

Read more ››
By: Nasdaq / GlobenewsWire - 25 Sep 2017

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

Read more ››
By: Nasdaq / GlobenewsWire - 25 Sep 2017
Related companies:  argenx SE

Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMD

Read more ››
By: Nasdaq / GlobenewsWire - 25 Sep 2017
Related companies:  Summit Therapeutics plc | Summit Medical Products, Inc. | Great Summit Co., Ltd. | Summit Biosciences Inc.

Majority of women do not know early signs of breast cancer, finds global survey by Avon

LONDON, Sept. 25, 2017 /CNW/ -- Only two in five people (42%) are confident about recognising the changes to their breasts that could be a sign of cancer, according to a new survey of 19,000 respondents by Avon Products, Inc., the world's leading social selling company([i]). The findings also... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017

SciBase Unveils Growth Strategy Including Plans for US Launch of Nevisense

STOCKHOLM, Sept. 25, 2017 /PRNewswire/ -- Following the Pre-Market Approval (PMA) of Nevisense in the US in June, SciBase today presents an update of their strategic growth plan. The focus of the plan is SciBase's entry into the US market, the continued growth in the core market Germany, and... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017

AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

LONDON and PHILADELPHIA, Sept. 25, 2017 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options, today provided an update with regard to the... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  AMO Pharma Limited

DSM Updates Market on Strategy 2018

HEERLEN, The Netherlands, September 25, 2017 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  DSM

Global Experts in Urban Health Meet to Address the Challenges and Opportunities of Urbanization

NEW YORK, September 25, 2017 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  Kremers Urban Pharmaceuticals Inc

Soligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine Candidate

PRINCETON, N.J., Sept. 25, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Soligenix will... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  Soligenix, Inc.

Sciton Launches Project Pink diVa Campaign with Young Survival Coalition Sponsorship

PALO ALTO, Calif., Sept 25, 2017 /PRNewswire/ -- Sciton, Inc. is pleased to announce a partnership between its Women's Health Group division and the Young Survival Coalition. The Women's Health Group, as part of Sciton's "Because Results Matter" mission and making a difference in the quality... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  Sciton, Inc.

Technical Reports on Biotech Equities -- Opko Health, Otonomy, Pacific Biosciences of California, and Portola Pharma

NEW YORK, September 25, 2017 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  PACIFIC BIOSCIENCES | Portola Pharmaceuticals Inc. | Otonomy, Inc.

eTheRNA immunotherapies Awarded EUR1 Million Grant From Flanders Innovation & Entrepreneurship to Further Upgrade its State-of-the-art Production Process for TriMix mRNA Immunotherapies

NIEL, Belgium, September 25, 2017 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2017

TapImmune Appoints Peter Hoang as President and Chief Executive Officer

JACKSONVILLE, Fla., Sept. 25, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, today announced that the... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  TapImmune Inc.

Today's Research Report Coverage on Medical Equipment Stocks -- AcelRx Pharma, GenMark Diagnostics, ViewRay, and Nevro

NEW YORK, September 25, 2017 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  GenMark Diagnostics, Inc. | AcelRx Pharmaceuticals, Inc. | Nevro Corp. | ViewRay Incorporated

Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease

MALVERN, Pa., Sept. 25, 2017 /PRNewswire/ -- Ocugen, Inc., a clinical stage biopharmaceutical company developing novel treatments for sight-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for OCU310... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  Ocugen

Lannett's Board Of Directors Initiates CEO Search

PHILADELPHIA, Sept. 25, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that its board of directors has begun a search for a new chief executive officer (CEO). As part of the unanimously approved search process, the board has retained a leading executive search firm to... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  Lannett Company, Inc.

SI-BONE, Inc. Announces Publication of iMIA - a 2nd Multicenter Randomized Controlled Trial of the iFuse Implant System® vs Conservative Care

SAN JOSE, Calif., Sept. 25, 2017 /PRNewswire/ -- SI-BONE, Inc., an innovative medical device company which pioneered the use of the iFuse Implant System(┬«) (iFuse), a triangular-shaped minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI)... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  SI-BONE, Inc.

PDL BioPharma Announces New $25 Million Share Repurchase Program

INCLINE VILLAGE, Nev., Sept. 25, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) announced today that PDL's board of directors has authorized a new stock repurchase program to acquire up to $25 million of the Company's common stock. Purchases may be made in open-market... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017

SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer

SAN DIEGO, Calif., Sept. 25, 2017 /PRNewswire-iReach/ -- SignalRx Pharmaceuticals Inc. today announced the presentation of scientific data on the company's in silico platform technology for the rational design of dual small-molecule PI3K/BRD4 inhibitor for immune-oncology relative to... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
Related companies:  SignalRx Pharmaceuticals, Inc.

Boston Scientific Announces U.S. FDA Approval for MRI Labeling on High-Voltage Devices and U.S. Launch of Resonate(TM) Devices with the HeartLogic(TM) Heart Failure Diagnostic

MARLBOROUGH, Mass., Sept. 25, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has launched the Resonate(TM) family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic(TM) Heart Failure Diagnostic to help... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2017
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
to the top ↑